Burtness, B.,
Haddad, R.,
Dinis, J.,
Trigo, J.,
Yokota, T,
De Souza Viana, L.,
Romanov, I.,
Vermorken, J.,
Bourhis, J.,
Tahara, M.,
Martins Segalla, J.G.,
Psyrri, A.,
Vasilevskaya, I.,
Nangia, C.S.,
Chaves-Conde, M.,
Kiyota, N.,
Homma, A.,
Holeckova, P.,
Del Campo, J.M.,
Asarawala, N.,
Nicolau, U.R.,
Rauch, D.,
Even, C.,
Wang, B.,
Gibson, N.,
Ehrnrooth, E.,
Harrington, K.,
Cohen, E.E.W. (2019) of randomization to the date of
tumor recurrence or secondary primary
tumor or death from any cause. Secondary end
YANG, G.,
LIU, Z.,
CHEN, X.,
WANG, X.,
ZHANG, D.,
YANG, Z.,
SUN, J.,
XUE, L.,
GAO, M.,
LI, L.,
GAREEV, I.,
ZHAO, S.,
WANG, L.,
DONG, Q.,
ZHOU, Q.,
YI, R.,
AI, J. (2019) of lentiviral vector. The inflammatory cytokines
tumor necrosis factor-α (TNFα), interleukin (IL)-1b, and IL-6
Bogliolo, M.,
Catucci, I.,
Caleca, L.,
Lasheras, S.V.,
Pujol, R.,
Kiiski, J.I.,
Muranen, T.A.,
Barnes, D.R.,
Dennis, J.,
Michailidou, K.,
Bolla, M.K.,
Leslie, G.,
Figlioli, G. (2019) exposure, identifies a possible therapeutic option to treat FANCM-associated
tumors. © 2019, The Author(s).